Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity (SPIROTOX)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 264 participants.

Also called NCT06005259

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 264 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06005259
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Brazil (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT06005259. Randomized; triple masking; primary purpose prevention. Start 2023-10-01 (anticipated); primary completion 2025-10-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity (SPIROTOX)
Acronym
SPIROTOX
Condition
Cardiotoxicity
Condition
Neoplasms
Condition
Chemotherapy Effect
Condition
Heart Failure
Intervention (Drug)
Spironolactone
Intervention (Drug)
Placebo
Lead sponsor
University of Sao Paulo (class: other)

Record details

Record id
cardio:ct-nct06005259
Content hash
24aa5f63e7b350f0f0e6f0e41aca42129ae6fe8cf148d722334bd7cd991a5271